Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
10/25/2019
Trade Name:
Opana
Generic Name or Proper Name (*):
oxymorphone HCl
Indications Studied:
Postoperative pain
Label Changes Summary:
*Safety and effectiveness for pediatric patients, 0 to 17 years, have not been established. *An open-label study was conducted in 58 pediatric patients 12 years and older with postoperative pain. Efficacy was not demonstrated in this population treated with doses expected to be comparable to effective starting doses in adults. *Pharmacokinetic results demonstrated that treatment with Opana tablets resulted in substantially higher systemic exposures to oxymorphone in 2 out of 24 patients. *Not recommended for use in the pediatric population. *Postmarketing study.
PREA(P):
P
Sponsor:
Endo
NNPS:
FALSE
Therapeutic Category:
Analgesic
-
-